PRMT5 and neoplasm: Notably, compared to the C57BL/6 mice group, there was a significant increase in tumor volumes and weights in the PRMT5 knockdown groups with CD8 deficiency, which corresponded to lower survival rates than those observed in the control group (Figure 3A–D).